Lung Cancer

Data from French trial should inform treatment decisions in the majority of lung cancer patients aged 70 and up. More »

Results of a long-term intergroup study on the effect of selenium in early non-small-cell lung cancer highlight the differences between smokers and nonsmokers, and support the thesis that “good” supplements may be harmful in the presence of carcinogens. More »

Success of adaptive randomization in BATTLE could provide new strategy in cancer trials. NSCLC also gain another tool for maintenance therapy. More »

Results of a new study published in the Annals of Internal Medicine [Ann Intern Med 152:505-512, 2010] indicate that the risk for false-positive results of CT lung cancer screening tests is substantial. Led by Jennifer M. Croswell, MD, researchers from NCI sought to quantify the cumulative risk in a 1- or 2-year lung cancer screening exam, based on at least one false-positive finding. More »

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC). More »

It is estimated that more than 1.5 million individuals in the United States will be diagnosed with cancer this year. Of these, nearly 145,000 will be diagnosed with non–small-cell lung cancer (NSCLC). More »

The review by Oxnard and Miller provides a thoughtful update on the use of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib (Iressa) and erlotinib (Tarceva) as front-line therapy in patients with non–small-cell lung cancer (NSCLC). More »

African Americans have a higher mortality rate from lung cancer than Caucasians, a fact first discovered in the early 1980s. For decades, researchers have looked for differences in access to care, rates of surgery, and patient preferences to explain the disparity. Now it seems the answer may relate at least partly to the way African Americans think about lung cancer. More »

An estimated 219,440 new cases of lung cancer were expected in 2009, accounting for about 15% of cancer diagnoses. More »

Probably no other topic in thoracic oncology has resulted in more controversy than that of the management of locally advanced non–small-cell lung cancer (NSCLC). Although recent large randomized studies have yielded more reliable and objective data on which to base treatment decisions than were available a decade ago, management of these patients is still influenced by specialty bias and philosophical beliefs. More »